Medical Advisory Board

Prof. Feagan is Professor of Medicine at the Division of Gastroenterology, Department of Medicine, Epidemiology and Biostatistics, Western University, and Senior Scientific Officer, Robarts Clinical Trials Inc, London, Ontario, Canada. A Fellow of the Royal College of Physicians and Surgeons of Canada, Dr. Feagan holds membership in the Canadian and American Association of Gastroenterology, the American College of Gastroenterology, the College of Physicians and Surgeons of Ontario, Crohn’s and Colitis Canada (CCC) and the European Crohn’s & Colitis Organisation (ECCO).

He has authored over 200 articles, book chapters and has also given over 900 invited presentations, at national and international scientific meetings. His research focuses on the design and implementation of randomized controlled trials for IBD.

Oliver has over 20 years of C-level leadership experience & operational R&D management spread across Pharma & Biotech, including over 15 years’ leadership experience in taking innovative Nucleic Acid (NA) and mRNA therapies from conception and discovery to market (in IBD & Oncology).
Oliver also has experience of leading Corporate and Business Development activities, partnering and licensing of life science products to large Pharma as well as out-licensed drug and diagnostic assets with an aggregate deal value of over €250m. He is a founder of vS Health Technologies GmbH, iModia Biotech GmbH & InDex Pharmaceuticals AB.

Lorin co-founded Salix Pharmaceuticals, Inc. (Nasdaq: SLXP), a leading specialized gastrointestinal products company. He also held senior leadership positions at Salix prior to its subsequent sale to Valeant Pharmaceuticals International, Inc. (NYSEA: VRX) for $15.8bn. Currently Lorin is a Board member of Glycyx MOR, Inc. (Delaware) and Kinisi Therapeutics, Ltd. (Isle of Man) & Intact Inc. (California). All are GI specialty drug development companies. He has held academic positions at Stanford University School of Medicine and the University of California, San Francisco, and is co-author of 75 journal articles and book chapters. Lorin is the co inventor on 22 issued patents and holds a Ph.D. from the University of Southern California and was a Postdoctoral Fellow at the University of California, San Francisco.

Mike has 36 years of pharmaceutical experience with GSK covering chemical development, manufacturing and CMC regulatory affairs. He has a track record of delivering robust processes and analytical methods to manufacturing and successful marketing submissions, and has extensive consulting experience with therapeutic oligonucleotides. Mike initiated GSK’s chemistry support for oligonucleotides and, for a period of over 6 years, led UK development chemistry for GSK as Vice President of API Chemistry & Analysis UK. Mike has published a number of papers, presented at a number of international meetings and co edited 3 books on Analytical Chemistry. He holds a PhD in Chemistry from Imperial College, an MSc in Molecular Spectroscopy and a BSc in Chemistry.